{"nctId":"NCT01217307","briefTitle":"Metformin to Reduce Heart Failure After Myocardial Infarction","startDateStruct":{"date":"2011-01"},"conditions":["ST Elevation Myocardial Infarction (STEMI)","Coronary Artery Disease","Heart Failure","Diabetes"],"count":380,"armGroups":[{"label":"Metformin","type":"EXPERIMENTAL","interventionNames":["Drug: Metformin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Metformin","otherNames":["Glucophage"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The diagnosis acute MI defined by chest pain suggestive for myocardial ischemia for at least 30 minutes, the time from onset of the symptoms less than 12 hours before hospital admission, and an ECG recording with ST- segment elevation of more than 0.1 mV in 2 or more leads.\n* Successful primary PCI (post-procedural TIMI 2/3);\n* At least one stent sized ≥ 3.0 mm;\n* Eligible for 3T CMR imaging;\n* Verbal followed by written informed consent.\n\nExclusion Criteria:\n\n* rescue PCI after thrombolytic therapy;\n* need for emergency coronary artery bypass grafting;\n* creatinin \\>177 μmol/L measured pre-PCI;\n* Younger than 18 years;\n* Mechanical ventilation;\n* Diabetes;\n* Prior myocardial infarction;\n* Contra-indication to metformin (see safety);\n* The existence of a life-threatening disease with a life-expectancy of less than 6 months.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Improvement in Left Ventricular Ejection Fraction","description":"The primary efficacy parameter of the GIPS-III trial is LVEF measured by cardiac MRI 4 months after randomization, based on an intention-to-treat analysis. It is hypothesized that metformin therapy will result in a higher ejection fraction after 4 months.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.1","spread":null},{"groupId":"OG001","value":"54.8","spread":null}]}]}]},{"type":"SECONDARY","title":"the Incidence of a Cardiovascular Event","description":"Cardiovascular events include major cardiac adverse events (MACE; death, recurrent MI, target lesion revascularization), stroke, non-elective hospitalizations for chest pain or heart failure, all recurrent coronary interventions, and internal cardiac defibrillator implantations. Mortality will be divided into cardiac and non-cardiac. Cardiac death will be divided into three categories: heart failure, sudden death and other. A cardiologist will confirm deaths from cardiovascular causes by examining medical records obtained from hospitals and attending physicians or from attending general practitioner if the patient died at home.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Markers of Heart Failure and Glycometabolic State","description":"markers of heart failure: neurohormones (e.g. NT-proBNP), renal function (e.g. MDRD); glycometabolic state: e.g. HbA1c.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Myocardial Infarct Size and Transmural Extent of Infarction as Measured With Cardiac Magnetic Resonance Imaging","description":"myocardial infarct size and transmural extent of infarction will be measured using Late Gadolinium Enhancement cardiac magnetic imaging","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Diastolic Function","description":"echocardiographic analysis of diastolic function","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Glycometabolic State","description":"measured by oral glucose tolerance testing and Glycated Hemoglobin according to current criteria","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Cardiac MRI After 4 Months, Per Protocol Analysis","description":"A per-protocol analysis, excluding patients diagnosed with new onset diabetes and treated with oral antihyperglycemic agents or insulin prior to cardiac MRI, will be performed as a secondary efficacy parameter","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":191},"commonTop":["Non-target lesion revascularization","Hospitalization for chest pain","CABG"]}}}